| NovoTTF-200A Together With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GBM (NCT03869242) | Tel-Aviv Sourasky Medical Center | 2018-10-01 |
| Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma (NCT03661723) | Dana-Farber Cancer Institute | 2018-09-28 |
| Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 (NCT02655601) | BioMimetix JV, LLC | 2018-09-25 |
| Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (NCT03493932) | National Institute of Neurological Disorders and Stroke (NINDS) | 2018-09-24 |
| Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 (NCT03679754) | Alaunos Therapeutics | 2018-09-05 |
| OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma (NCT03587038) | University of Oklahoma | 2018-09-03 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme (NCT03025893) | Amsterdam UMC, location VUmc | 2018-08-31 |
| Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma (NCT03535350) | Case Comprehensive Cancer Center | 2018-08-24 |
| Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients (NCT03626896) | NaviFUS Corporation | 2018-08-17 |
| Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (NCT03389230) | City of Hope Medical Center | 2018-08-14 |
| Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma (NCT03452930) | M.D. Anderson Cancer Center | 2018-08-13 |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM (NCT03630289) | Northwell Health | 2018-07-27 |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer (NCT03107780) | National Cancer Institute (NCI) | 2018-07-09 |
| Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma (NCT03287063) | University of Michigan Rogel Cancer Center | 2018-07-05 |
| A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 (NCT03636477) | Alaunos Therapeutics | 2018-06-18 |
| Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers (NCT04630379) | Mayo Clinic | 2018-06-13 |
| Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma (NCT03341806) | Icahn School of Medicine at Mount Sinai | 2018-06-13 |
| Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma. (NCT03224104) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-06-12 |
| Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma (NCT03514069) | Case Comprehensive Cancer Center | 2018-06-05 |
| Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery (NCT05873946) | Hospital del Rio Hortega | 2018-06-01 |
| INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (NCT03491683) | Inovio Pharmaceuticals | 2018-05-31 |
| Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM (NCT03452579) | David Peereboom | 2018-05-21 |
| A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas (NCT03593993) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-05-19 |
| Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma (NCT03477110) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-05-04 |
| Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma (NCT03687099) | Centre Hospitalier Universitaire, Amiens | 2018-04-30 |
| Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy (NCT03548571) | Oslo University Hospital | 2018-04-26 |
| [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers (NCT03539731) | Guido A. Davidzon, MD, SM | 2018-04-23 |
| Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma (NCT03451799) | Jethro Hu | 2018-04-13 |
| Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1) (NCT03392545) | Beijing Tiantan Hospital | 2018-04-01 |
| Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme (NCT03363659) | Wake Forest University Health Sciences | 2018-03-28 |
| Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma (NCT03246113) | New York State Psychiatric Institute | 2018-03-19 |
| Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma (NCT03426891) | H. Lee Moffitt Cancer Center and Research Institute | 2018-03-16 |
| Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms (NCT03877861) | Allina Health System | 2018-03-15 |
| Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma (NCT03395587) | Heinrich-Heine University, Duesseldorf | 2018-03-06 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors (NCT03434262) | St. Jude Children's Research Hospital | 2018-03-05 |
| Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma) (NCT03463733) | M.E. van Linde | 2018-03-02 |
| Phase I EGFR BATs in Newly Diagnosed Glioblastoma (NCT03344250) | University of Virginia | 2018-03-01 |
| Personalized Radiation Therapy for GBM (NCT03477513) | Abramson Cancer Center at Penn Medicine | 2018-03-01 |
| Chloroquine for Glioblastoma. (NCT04772846) | Egyptian Medical Syndicate | 2018-03-01 |
| HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM (NCT03603405) | The Methodist Hospital Research Institute | 2018-02-28 |
| Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) (NCT03405792) | University of Florida | 2018-02-23 |
| Easing Psychosocial Burden for Informal Caregivers (NCT03454295) | Memorial Sloan Kettering Cancer Center | 2018-02-12 |
| Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma (NCT03439332) | Juan M Garcia-Gomez | 2018-02-07 |
| Bioavailability of Disulfiram and Metformin in Glioblastomas (NCT03151772) | Sahlgrenska University Hospital | 2018-01-29 |
| HMPL-813 in Treating Patients With Glioblastoma (NCT03231501) | Hutchison Medipharma Limited | 2018-01-26 |
| Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (NCT03393000) | Diffusion Pharmaceuticals Inc | 2018-01-16 |
| Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma (NCT03197506) | Mayo Clinic | 2018-01-15 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence (NCT04846257) | Egyptian Medical Syndicate | 2018-01-01 |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors (NCT02684058) | Novartis Pharmaceuticals | 2017-12-28 |
| Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma (NCT03347617) | OHSU Knight Cancer Institute | 2017-12-20 |
| Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression (NCT03050736) | Kintara Therapeutics, Inc. | 2017-12-17 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (NCT03149003) | Sumitomo Pharma America, Inc. | 2017-12-08 |
| A Trial of KB004 in Patients With Glioblastoma (NCT03374943) | Olivia Newton-John Cancer Research Institute | 2017-12-05 |
| BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma (NCT03119064) | Brown University | 2017-11-30 |
| A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) (NCT03355794) | Children's Hospital Medical Center, Cincinnati | 2017-11-14 |
| Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children (NCT03043391) | Istari Oncology, Inc. | 2017-11-07 |
| CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma (NCT03152708) | CANbridge Life Sciences Ltd. | 2017-11-01 |
| Spectral Analysis Probe to Identify Glioblastoma Cells (NCT03293888) | University of Oklahoma | 2017-10-31 |
| VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM (NCT03149575) | DelMar Pharmaceuticals, Inc. | 2017-10-27 |
| Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients (NCT03294486) | Assistance Publique - Hôpitaux de Paris | 2017-10-12 |
| Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma (NCT03278249) | University of Cincinnati | 2017-10-12 |
| Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma (NCT03567135) | Fuzhou General Hospital | 2017-10-01 |
| Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (NCT03018288) | National Cancer Institute (NCI) | 2017-09-21 |
| Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma (NCT03139916) | Massachusetts General Hospital | 2017-09-13 |
| Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma (NCT04974983) | University Hospital Regensburg | 2017-09-01 |
| Prognosis and Therapeutic Biomarkers for Glioblastoma Patients (NCT03403803) | Baylor Research Institute | 2017-09-01 |
| TTFields In GErmany in Routine Clinical Care (NCT03258021) | NovoCure Ltd. | 2017-08-31 |
| Exercise in Patients With Glioblastoma (NCT03390569) | University Health Network, Toronto | 2017-08-29 |
| Feasibility Study on LITT for Newly Diagnosed Glioblastoma (NCT02880410) | Monteris Medical | 2017-08-15 |
| Mind-Body Intervention in Glioma Couples (NCT03244995) | M.D. Anderson Cancer Center | 2017-08-06 |
| A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (NCT02869243) | Stemgen | 2017-07-18 |
| A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (NCT03152318) | Dana-Farber Cancer Institute | 2017-07-18 |
| Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma (NCT03251027) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-07-17 |
| Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma (NCT03174197) | M.D. Anderson Cancer Center | 2017-06-30 |
| Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM (NCT03213002) | Northwell Health | 2017-06-13 |
| Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma (NCT02743078) | RTOG Foundation, Inc. | 2017-05-09 |
| INtraoperative photoDYnamic Therapy of GliOblastoma (NCT03048240) | University Hospital, Lille | 2017-05-05 |
| Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness (NCT06348693) | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 2017-04-19 |
| Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma (NCT02858895) | Medicenna Therapeutics, Inc. | 2017-04-11 |
| A Phase I Clinical Trial of Bevacizumab Injection (NCT05476341) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-04-06 |
| Ketogenic Diets as an Adjuvant Therapy in Glioblastoma (NCT03075514) | University of Liverpool | 2017-04-01 |
| Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma (NCT02968940) | NYU Langone Health | 2017-03-17 |
| RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (NCT02871843) | EpicentRx, Inc. | 2017-02-14 |
| A Study of Abemaciclib in Recurrent Glioblastoma (NCT02981940) | Dana-Farber Cancer Institute | 2017-02-09 |
| Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma (NCT03055208) | Universitätsmedizin Mannheim | 2017-02-08 |
| EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (NCT02664363) | Daniel Landi | 2017-02-01 |
| Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting (NCT02717962) | Kintara Therapeutics, Inc. | 2017-01-20 |
| Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach (NCT07420543) | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 2017-01-18 |
| A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (NCT02866747) | Institut Claudius Regaud | 2017-01-17 |
| BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab (NCT03020602) | Seema Nagpal | 2017-01-04 |
| Disulfiram in Recurrent Glioblastoma (NCT02678975) | Sahlgrenska University Hospital | 2017-01-01 |
| TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma (NCT02663271) | University of Florida | 2016-12-19 |
| Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme (NCT02685605) | Universitätsmedizin Mannheim | 2016-12-09 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens (NCT02864368) | Eric Thompson, M.D. | 2016-12-07 |
| Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCT02997423) | University of Iowa | 2016-11-30 |
| Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma (NCT03243851) | Yong-Kil Hong | 2016-11-21 |
| A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. (NCT03233152) | Universitair Ziekenhuis Brussel | 2016-11-17 |
| A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma (NCT02754362) | NYU Langone Health | 2016-11-01 |